首页> 美国卫生研究院文献>other >Behavioral effects of the R-(+)- and S-(−) enantiomers of the D1-like partial receptor agonist SKF 83959 in monkeys
【2h】

Behavioral effects of the R-(+)- and S-(−) enantiomers of the D1-like partial receptor agonist SKF 83959 in monkeys

机译:D1样部分受体激动剂SKF 83959的R-(+)-和S-(-)对映体在猴子中的行为效应

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

Dopamine D1-like partial receptor agonists such as SKF 83959 have been proposed as potential candidates for the treatment of cocaine addiction. The present studies were conducted to further characterize SKF 83959 by pharmacologically evaluating effects of its R-(+)- and S-(−) enantiomers, MCL 202 and MCL 201, respectively, on overt behavior (eye blinking) and schedule-controlled performance in squirrel monkeys. MCL 202, like the D1 full receptor agonist SKF 82958, produced dose related increases in eye blinking and decreases in rates of fixed-ratio responding. However, the magnitude of effects of MCL 202 on eye blinking was less than observed with SKF 82958. In contrast to the effects of its R-(+) enantiomer, MCL 201 was relatively devoid of behavioral activity up to doses that were approximately 10-fold greater than MCL 202. Pretreatment with the selective D1-like receptor antagonist SCH 39166 dose-dependently antagonized increases in eye blinking produced by MCL 202, confirming the involvement of D1 mechanisms in its effects. A dose-ratio analysis of the antagonism of effects of MCL 202 by SCH 39166 revealed an apparent pA2 value of 7.675 with a slope of −0.78 ± 0.04. In further studies, pretreatment with MCL 202 antagonized the effects of SKF 82958 on eye blinking and, like SCH 39166, schedule-controlled behavior in a dose-related manner. A dose-ratio analysis of the antagonist effects of MCL 202 on the SKF 82958-induced increases in eye blinking revealed ratios of 2.7, 4.8 and 31.1 for 0.1, 0.3 and 1.0 mg/kg dose of the antagonist, respectively, indicative of a significant change in the potency of SKF 82958. These results suggest that MCL 202, like its parent compound SKF 83959, has both D1 receptor-mediated agonist and antagonist properties, consistent with its characterization as a partial agonist at the D1-like receptor. In addition, the inactivity of MCL 201, the S-(−)-enantiomer, suggests that the behavioral effects of SKF 83959 can be attributed primarily to the activity of its R-(+)-enantiomer.
机译:已提议将多巴胺D1样的部分受体激动剂(例如SKF 83959)用作治疗可卡因成瘾的潜在候选药物。进行本研究以通过药理学评估其R-(+)-和S-(-)对映异构体MCL 202和MCL 201分别对明显行为(眨眼)和进度控制性能的作用来进一步表征SKF 83959在松鼠的猴子。像D1全受体激动剂SKF 82958一样,MCL 202产生与剂量相关的眨眼次数增加和固定比率响应率降低。但是,MCL 202对眨眼的影响幅度小于用SKF 82958观察到的程度。与其R-(+)对映体的影响相比,MCL 201在大约10-比MCL 202大两倍。用选择性D1样受体拮抗剂SCH 39166进行的剂量依赖性拮抗MCL 202产生的眨眼,证实了D1机制参与了其作用。 SCH 39166对MCL 202的拮抗作用进行了剂量比分析,结果显示pA2的表观值为7.675,斜率为-0.78±0.04。在进一步的研究中,使用MCL 202进行预处理可拮抗SKF 82958对眨眼的影响,并且与SCH 39166一样,以剂量相关的方式控制时间表控制的行为。 MCL 202对SKF 82958引起的眨眼增加的拮抗剂作用的剂量比分析显示,分别以0.1、0.3和1.0 mg / kg剂量的拮抗剂,其比率分别为2.7、4.8和31.1。改变SKF 82958的效力。这些结果表明,MCL 202与其母体化合物SKF 83959一样,具有D1受体介导的激动剂和拮抗剂特性,与其在D1样受体处作为部分激动剂的特征一致。另外,MCL 201(S-(-)-对映异构体)的无活性表明,SKF 83959的行为效应主要归因于其R-(+)-对映异构体的活性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号